The Institute of Chemical and Engineering Sciences (ICES), a research institute under the Agency for Science, Technology and Research, signed a research collaboration agreement with MerLion Pharmaceuticals Pte Ltd to synthesise and develop novel molecules, based upon naturally derived compounds, for anti-tumour drug therapies. The agreement was signed by Dr Tony Buss, President and CEO of MerLion and Dr Keith Carpenter, Executive Director of ICES.